Mylan Loses Appeal In Duragesic Patent Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Company's latest effort to launch its generic fentanyl patch before Duragesic pediatric exclusivity expires in January is rebuffed by the Federal Circuit, which finds that J&J’s patent is valid and Mylan’s ANDA infringes. The ruling marks the second appellate court loss on fentanyl in less than a month for Mylan.